The application of CRISPR technology to mitochondrial DNA (mtDNA) has long been hindered by the difficulty of delivering single-guide RNAs (sgRNAs) into mitochondria. However, a recent breakthrough has overcome this barrier, paving the way for targeted gene editing in conditions like Maternally Inherited Diabetes and Deafness (MIDD).
Researchers have developed an innovative RMTS-CRISPR tool that utilizes RNA mitochondrial targeting sequences (RMTS) derived from mitochondria-associated long noncoding RNAs (lncRNAs). By integrating these RMTSs into the components of sgRNAs, the team successfully constructed molecular tools capable of entering the mitochondria and facilitating RNA-guided double-strand breaks in mtDNA.
MIDD is predominantly caused by the m.3243A>G mutation in the mitochondrial genome, which impairs mitochondrial respiratory chain function and leads to pancreatic β-cell dysfunction and insulin resistance. The RMTS-CRISPR tool was applied to patient-derived cells harboring this heteroplasmic mtDNA mutation. The results demonstrated that the tool could effectively reduce the mutant mtDNA load and restore mitochondrial function.
This advancement is particularly significant because traditional CRISPR-Cas9 systems have shown exceedingly low knockin efficiency in mitochondria, largely due to ineffective sgRNA delivery. By harnessing the natural transport mechanisms of lncRNAs, the RMTS-CRISPR system achieves efficient mitochondrial targeting. This novel approach not only expands the utility of CRISPR in mitochondrial genome therapy but also provides a promising intervention strategy for reducing the pathogenic burden in patients with MIDD.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.